Company intelligence / Profile preview

Immunity Pharma

Ownership: Private
Development stage: Phase 2

Overview

Immunity Pharma has reported positive topline results from a Phase 2a trial of its lead candidate IPL344 in ALS patients, including evidence of safety, tolerability, and clinically significant slowdown in disease progression. Biomarker data showed a reduction in plasma neurofilament-light concentrations indicating reduced neuronal degeneration. The company also holds Orphan Drug Designation for IPL344 from both FDA and EMA. Additional pipeline projects are at the research/preclinical stage[1][2].

Therapeutic areas: ImmunologyNeurology
Modalities: Peptides (notably novel peptides such as IPL344)[2]Small molecule Akt activators (preclinical)[2]
Industry: Biotech

Drug pipeline

3 assets

IPL344

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Immunity Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunity Pharma.

Explore the full profile